Novonco Therapeutics

This company develops small molecule drugs targeting ribonucleotide reductase, DNA repair, and kinases to treat solid and hematologic cancers. Their personalized medicine approach aims to provide molecularly-targeted therapeutics for cancer patients.

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Many cancer treatments are not effective because they treat all patients the same way, failing to account for individual differences in tumor biology and drug resistance. Existing cancer therapies often have significant drawbacks, including short half-lives, drug resistance, and damage to non-cancer cells, leading to severe side effects.

Solution

Novonco Therapeutics develops precision medicine therapeutics, based on natural products, designed to target the unique molecular characteristics of individual cancers. The company's small molecule drugs target ribonucleotide reductase (RR), DNA repair mechanisms, histone methyltransferases, and kinases, which are crucial for cancer cell growth and survival. By inhibiting these targets, Novonco's therapies aim to selectively disrupt cancer cell function while minimizing harm to healthy cells. These therapies offer potential treatments for patients with solid and hematologic cancers, including those with limited treatment options or drug-resistant tumors.

Target Audience

The primary target audience includes cancer patients with solid and hematologic malignancies, particularly those with limited treatment options, as well as oncologists and researchers seeking more effective and personalized cancer therapies.

Features

COH29: A small molecule inhibitor of ribonucleotide reductase (RR) and DNA repair, shown in preclinical studies to reduce tumor growth in human cancers, including leukemia and ovarian cancer.
NV10: A small molecule inhibitor of histone methyltransferase SUV39H1, demonstrating anticancer activity in vitro and in vivo in several cancer cell lines, including hepatocellular carcinoma and acute myeloid leukemia.
Indirubin Analogs: Selective kinase inhibitors derived from a natural product used in Traditional Chinese Medicine, with potential for treating solid tumors such as lung cancers and relapsed acute myelogenous leukemia with FLT3 mutations.
Molecularly-targeted action mechanisms that limit damage to non-cancer cells, reducing side effects.
Potential to overcome hydroxyurea- and gemcitabine-resistance in cancer cells.